Loading...
Prothena Community
NasdaqGS:PRTA Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
Community Investing Ideas
Analysts Maintain Prothena Price Target as Valuation Adjustments Reflect Recent Clinical Results
Key Takeaways Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities. Strategic partnerships and a strong financial position support pipeline advancement and potential long-term earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$20.33
45.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
90.87% p.a.
Profit Margin
16.03%
Future PE
101.74x
Price in 2028
US$24.82
